Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocodone bitartrate + acetaminophen + gamma-aminobutyric acid is an oral combination product marketed as **Theracodophen**, developed by Physician Therapeutics for the dietary management of myalgia and of pain and inflammation. The product combines hydrocodone bitartrate and acetaminophen tablets with separate capsules containing gamma-aminobutyric acid as part of a medical food formulation. Pharmacologically, hydrocodone is a small-molecule **mu-opioid receptor agonist** that provides opioid analgesia, while acetaminophen is a non-opioid analgesic and antipyretic with central pain-relieving activity; the gamma-aminobutyric acid component is presented as a nutritional or medical food ingredient rather than as an FDA-approved active pharmaceutical ingredient for these uses. Available information indicates the labeling was not approved by FDA and the product was not found by FDA to be safe and effective.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocodone bitartrate + acetaminophen + gamma-aminobutyric acid.